# Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

> **NCT04026178** · PHASE4 · COMPLETED · sponsor: **Aegerion Pharmaceuticals, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Generalized Lipodystrophy

## Interventions

- **DRUG:** Metreleptin

## Key facts

- **NCT ID:** NCT04026178
- **Lead sponsor:** Aegerion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-14
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026178, "Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04026178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*